Text Size

Biocompatibility and pharmacokinetic analysis of an intracameral polycaprolactone drug delivery implant for glaucoma

Kim J., Kudisch M., Mudumba S., Asada H., Aya-Shibuya E., Bhisitkul R.B., Desai T.A.


  • 2016
  • Investigative Ophthalmology and Visual Science
View publication
  • Therapeutic Area

    Glaucoma

  • Technology

    Drug Delivery

  • Affiliations

    San Francisco, CA, United States; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, United States; Santen, Inc., Emeryville, CA, United States; Santen Pharmaceutical Co., Ltd., Nara RD Center, Nara, Japan; Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, United States

Related Publications

Benefit of omidenepag isopropyl ophthalmic solution in treatment persistence in Japanese patients with glaucoma

Kashiwagi K., Nakano T., Nakazawa T., Fuwa M., Otsuka N., Shii D., Miyahara R.


Posterior Ciliary Artery Contraction by Bradykinin Receptor Subtypes and Implications for Retinal Blood Flow Dysfunction

Sharif NA, Ohia SE, Kulkarni-Chitnis M, Okolie A, Chaudhry SD, Njie-Mbye YF


Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A 3-Year Prospective Study

Akagi T, Fukuchi T, Higashide T, Udagawa S, Ohkubo S, Sugiyama K, Tanihara H, Araie M, Tomita G, Matsumoto C, Tomidokoro A, Hangai M, Kawata H, Inai M, Tanaka Y; SVF Prospector Study Group.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022